IceCure’s ProSense Cryoablation Gains Traction in Europe with Strong EUSOBI 2026 Data
Event summary
- ProSense® breast cancer cryoablation featured in multiple scientific presentations, research posters, and physician workshops at EUSOBI 2026.
- 12-month clinical data reported objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone.
- Two well-attended clinical workshops attracted nearly 70 participants each.
- Two scientific posters by ProSense® users presented at the conference.
The big picture
IceCure’s strong showing at EUSOBI 2026 underscores the growing interest in minimally invasive breast cancer treatments, particularly among elderly patients or those ineligible for surgery. The company’s ProSense® system is positioning itself as a key player in the shift toward less invasive cancer therapies, a trend driven by both patient preference and advancements in medical technology. The clinical data presented at the conference could accelerate adoption, particularly in Europe, where regulatory pathways and physician networks are critical to market penetration.
What we're watching
- Clinical Adoption
- How the strong physician engagement and clinical data will translate into broader adoption of ProSense® in Europe.
- Regulatory Expansion
- Whether the positive data will support regulatory approvals in additional markets beyond the current indications.
- Competitive Positioning
- The pace at which IceCure can differentiate ProSense® from surgical and other minimally invasive breast cancer treatments.
Related topics
